Company intelligence / Profile preview

BCI Pharma

Ownership: Private
Development stage: Preclinical

Overview

BCI Pharma has identified a preclinical candidate, BCI-1446, for treating peripheral neuropathic pain and psoriasis. The company has also entered partnerships for developing treatments for endometriosis and women's cancers. In June 2024, Gedeon Richter acquired BCI Pharma for EUR 12 million.

Therapeutic areas: ImmunologyDermatologyWomen's HealthOncologyNeurology
Modalities: Small moleculeskinase inhibitors
Industry: Biotech

Partnerships

Mithra PharmaceuticalsGedeon Richter Plc

Beyond the preview

Go deeper on BCI Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BCI Pharma.